Trials / Recruiting
RecruitingNCT07226349
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 105 (estimated)
- Sponsor
- BeOne Medicines · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
Detailed description
This study will be conducted in 2 phases: Phase 1a Dose Escalation and Phase 1b Dose Expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BG-75098 | Administered orally. |
| DRUG | BGB-43395 | Administered orally. |
| DRUG | Fulvestrant | Administered by intramuscular injection. |
Timeline
- Start date
- 2025-12-11
- Primary completion
- 2028-11-01
- Completion
- 2028-11-01
- First posted
- 2025-11-10
- Last updated
- 2026-04-15
Locations
16 sites across 4 countries: United States, Australia, China, Denmark
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07226349. Inclusion in this directory is not an endorsement.